Journal article
SGLT-2 inhibitors or GLP-1 receptor agonists for adults with type 2 diabetes: a clinical practice guideline
Abstract
CLINICAL QUESTION: What are the benefits and harms of sodium-glucose cotransporter 2 (SGLT-2) inhibitors and glucagon-like peptide 1 (GLP-1) receptor agonists when added to usual care (lifestyle interventions and/or other diabetes drugs) in adults with type 2 diabetes at different risk for cardiovascular and kidney outcomes?
CURRENT PRACTICE: Clinical decisions about treatment of type 2 diabetes have been led by glycaemic control for decades. …
Authors
Li S; Vandvik PO; Lytvyn L; Guyatt GH; Palmer SC; Rodriguez-Gutierrez R; Foroutan F; Agoritsas T; Siemieniuk RAC; Walsh M
Journal
The BMJ, Vol. 373, ,
Publisher
BMJ
DOI
10.1136/bmj.n1091
ISSN
0959-8138